Cas:884497-63-6 8-hydroxy-5-nitroquinoline-2-carbaldehyde manufacturer & supplier

We serve Chemical Name:8-hydroxy-5-nitroquinoline-2-carbaldehyde CAS:884497-63-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

8-hydroxy-5-nitroquinoline-2-carbaldehyde

Chemical Name:8-hydroxy-5-nitroquinoline-2-carbaldehyde
CAS.NO:884497-63-6
Synonyms:8-hydroxy-5-nitroquinoline-2-carbaldehyde
Molecular Formula:C10H6N2O4
Molecular Weight:218.16600
HS Code:2933499090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:492.9ºC at 760 mmHg
Density:1.572g/cm3
Index of Refraction:1.765
PSA:96.01000
Exact Mass:218.03300
LogP:2.18430

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 8-hydroxy-5-nitroquinoline-2-carbaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,8-hydroxy-5-nitroquinoline-2-carbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,8-hydroxy-5-nitroquinoline-2-carbaldehyde Use and application,8-hydroxy-5-nitroquinoline-2-carbaldehyde technical grade,usp/ep/jp grade.


Related News: It also said it would bar South Koreans from visiting China as tourists. 8-hydroxy-5-nitroquinoline-2-carbaldehyde manufacturer Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 8-hydroxy-5-nitroquinoline-2-carbaldehyde supplier Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS). 8-hydroxy-5-nitroquinoline-2-carbaldehyde vendor The FDA also said that the labeling of the diagnostic, which comes in different versions, included performance claims that did not match up with results seen in clinical studies—and that the data Innova submitted for review “was identical to data previously provided by other manufacturers” in separate requests for emergency COVID authorizations, raising additional questions. 8-hydroxy-5-nitroquinoline-2-carbaldehyde factory It also said it would bar South Koreans from visiting China as tourists.